Pomalidomide (marketed as Pomalyst in the U.S. and Imnovid in the EU and Russia) is a thalidomide analogue indicated, in combination with dexamethasone marketed by Celgene.
Imnovid (Pomalidomide) Indications:
In February 2013 U.S. Food and Drug Administration (FDA) approved Pomalidomide for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
DOSAGE FORM & STRENGTH:
Imnovid (Pomalidomide) 4mg wholesaler
Imnovid (Pomalidomide) 3mg distributor
Imnovid (Pomalidomide) 2mg supplier
Imnovid (Pomalidomide) 1m exporter
Rasso swiss pharma is a Imnovid (Pomalidomide) distributor, wholesaler, supplier.